Printer Friendly

Oncomatrix Launches a New Immunohistochemistry Kit to Diagnose and Prognose Tumor Invasiveness.

* Oncomatrix has associated genes and proteins in the peritumoral stroma to tumor invasiveness.

* Monoclonal antibodies have been raised against these stroma biomarkers.

* A multicenter clinical trial has shown sensitivity and specificity levels above 90%.

BALTIMORE -- The biopharmaceutical company Oncomatrix has developed and clinically validated a new immunohistochemistry-based kit to diagnose and prognose the invasiveness of different tumors, such as pancreas, breast, lung, colon and head & neck: DMTXinvaScan.

A large multicenter clinical trial has shown sensitivity and specificity levels higher than 90%.

Oncomatrix has identified a number of genes and proteins that are differentially expressed in tumor-associated stroma mesenchymal cells and extracellular matrix. The gen collagen XI-1, and its encoded protein, are expressed in the stroma fibroblasts that are associated to invasive tumors, but not in those fibroblasts that are associated to non-invasive tumors or to benign lesions or inflammatory processes.

Oncomatrix has developed and clinically validated a monoclonal antibody that detects collagen XI-1. This antibody is the main component of DMTXinvaScan, the Oncomatrix kit that enables an accurate diagnosis and prognosis of invasive tumors, facilitating the selection of patient cancer treatment.

DMTXinvaScan will be presented this week at the United States and Canadian Academy of Pathology USCAP meeting in Baltimore, USA, by Oncomatrix and their clinical and scientific collaborators from the Hospital Universitario Marques de Valdecilla in Spain.

About Oncomatrix

Oncomatrix is focused on the development of personalized biological treatments, to fight against invasive tumors. The company is based in the Bizkaia Technology Park, in the Basque Country, Spain.

Oncomatrix scientists have discovered new genes, proteins and mechanisms in the tumor-associated stroma cells and extracellular matrix, which trigger tumor invasiveness.

Oncomatrix carries out the development of Diagnostic devices and Antibody-Drug Conjugates and Immunotoxins against these novel targets, in collaboration with reference research centers, universities and hospitals in Europe and USA, such as National Jewish Health, Case Western Reserve University, University of Stuttgart, Hospital Universitario Marques de Valdecilla and Hospital Central de Asturias.

www.oncomatrix.es
COPYRIGHT 2013 Business Wire, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2013 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1U5MD
Date:Mar 4, 2013
Words:390
Previous Article:Prelert and CA Technologies Form OEM Relationship.
Next Article:New Chase Platinum Business Delivers Big Value to Small Business Customers.
Topics:

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters